Websites

The article "Low-load Θ-metallacarboranes as safe and efficient photoredox catalysts for UVA-driven oxidation in water" published in 2025 in Cell Reports Physical Science, by ICMAB, Universitat de Girona and Universitat de València, has been recently featured in UAB Divulga

Researchers at ICMAB combine paper-based lateral flow technology with organic electronics for achieving a fast, highly sensitive and label-free sensing platform. The study is published in the journal Advanced Materials. 

Since 1986 and up to 2024, ICMAB has authored over 6,500 publications that together have amassed more than 250,000 citations. In just 2024, our researchers contributed 247 articles—some of which have already earned “highly cited” status.

In this post, we share three specially curated lists: Highly cited papers of 2024, Most cited articles since 2014, and Most cited articles from all ICMAB history (1986–2024). The single most cited paper tops 11,000 citations—can you guess which one it is?

Our most cited ICMAB publications showcase breakthroughs in materials science, energy storage, computational chemistry, nanotechnology, quantum biology, and sustainable bioresources. Dive in to explore the landmark studies that define ICMAB’s legacy and drive its future impact.

Collaboration with academic and research institutions is a cornerstone of ICMAB’s scientific strategy. By partnering with leading organizations, both locally and internationally, ICMAB strengthens its research capabilities, fosters interdisciplinary innovation, and expands its impact across diverse scientific fields. These institutional collaborations not only support the exchange of knowledge and resources but also enhance the visibility and integration of ICMAB within the global research community. Here you will find our top institutions and countries with whom we have collaborated in 2024.

"It doesn't exist if it is not published", or "Publish or perish". For sure you have heard some of these sentences. Our ICMAB researchers do great science, and also publish the results in specialized scientific journals, to disseminate the research results they obtain. This year 2024 our researchers have published 247 research articles in many different journals, in the fields of physics, chemistry, materials, nanotechnology and more. A total of 140 different journals!

The Clarivate journal Impact Factor (IF) metric system gives a yearly numeric indicator of how much has an article been cited and how much impact has it had. With nearly 250 publication with IF, ICMAB's average IF has been 9.6, with 27% of the publications with an IF higher than 10. 

ICMAB-CSIC has been featured in the Spotlight Spain section of Nature, in an article that highlights Spain’s research centres as key players in global talent attraction. The piece showcases ICMAB’s multidisciplinary approach to materials science, addressing pressing challenges in electronics, energy and health.

La reunión, celebrada los días 7 y 8 de febrero, fue inaugurada por el vicerrector de Investigación y Transferencia de la Universidad de Granada, Enrique Herrera, y por la coordinadora del proyecto, Nora Ventosa, investigadora del CIBER y del ICMAB-CSIC; y ha contado con la presencia de 38 investigadores de los socios del consorcio procedentes del Centro de Investigación Biomédica en Red (CIBER) del Instituto de Ciencia de Materiales de Barcelona (ICMAB, del Centro de Investigación Biomédica en Red (CIBER), de la Universidad de Extremadura y la Universidad de Cantabria, del Consejo Superior de Investigaciones Científicas (CSIC), Nanomol Technologies S.L. (NT), Bioiberica S. A. U (BIO), Histocell S. L (HCELL) y Asphalion (ASPH); MyBiotech GmbH (MyB) y Charité-Universitätsmedizin Berlin (CH), de Alemania; del Instituto de Investigación Médica y Salud Laboral (IMI) de Croacia; de la Universidad de Aarhus (AU), de Dinamarca; del Technion-Israel Institute of Technology (IT), de Israel; de BioNanoNet Forschungsgesellschaft mbH (BNN), de Austria, y de la Universidad de Maribor (UM), de Eslovenia.

La inmunoterapia es uno de los campos de investigación más prometedores en la lucha contra el cáncer, pero necesita mucha investigación para superar ciertas limitaciones detectadas hasta ahora. Por ejemplo, en el caso de las inmunoterapias personalizadas basadas en células CAR-T es importante mejorar los sistemas de producción celulares para que tengan buena calidad y se puedan generar de forma rápida y económica. Las células CAR-T son linfocitos modificados genéticamente para que sean capaces de detectar el tumor de forma efectiva. Son, en otras palabras, el medicamento que se utiliza en las inmunoterapias celulares.